PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

doi:10.2337/db19-0973

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

Diabetes - 1 Apr 2020

Morieri Mario Luca, Shah Hetal S, Sjaarda Jennifer, Lenzini Petra A, Campbell Hannah, Motsinger-Reif Alison A, Gao He, Lovato Laura, Prudente Sabrina, Pandolfi Assunta, Pezzolesi Marcus G, Sigal Ronald J, Paré Guillaume, Marcovina Santica M, Rotroff Daniel M, Patorno Elisabetta, Mercuri Luana, Trischitta Vincenzo, Chew Emily Y, Kraft Peter, Buse John B, Wagner Michael J, Cresci Sharon, Gerstein Hertzel C, Ginsberg Henry N, Mychaleckyj Josyf C, Doria Alessandro

Abstract excerpt

The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of patients with type 2 diabetes who may derive cardiovascular benefit from addition of this treatment to statins. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Dyslipidemias

Share to Hypolipidemic Agents

Share to Lipids

Share to Pharmacogenetics

Share to PPAR alpha

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 31974142
DOI: 10.2337/db19-0973
PMCID: PMC7085251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.PMID 31974142Read ↗

Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy.Semantic proximity Read ↗

The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.Semantic proximity Read ↗

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Semantic proximity Read ↗

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.Semantic proximity Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

Pharmacogenetics of the PPAR genes and cardiovascular disease.Semantic proximity Read ↗

Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.Semantic proximity Read ↗

Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study.Semantic proximity Read ↗

A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes.Semantic proximity Read ↗

Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.Semantic proximity Read ↗

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.